Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model

References

• Gupta AK, Meena JP, Chopra A, Tanwar P, Seth R. Juvenile myelomonocytic leukemia-a comprehensive review and recent advances in management. Am J Blood Res. 2021;11(1):1–21.
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Loh ML. Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr. 2014;2:25. doi:10.3389/fped.2014.00025.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125(7):1083–1090. doi:10.1182/blood-2014-08-550483.
   PubMed Web of Science ®Google Scholar
• Krombholz CF, Aumann K, Kollek M, et al. Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-/- c-/- mice. Haematologica. 2016;101(5):597–606. doi:10.3324/haematol.2015.138545.
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Balasis ME, Vedder A, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017;130(4):397–407. doi:10.1182/blood-2017-01-763219.
   PubMed Web of Science ®Google Scholar
• Caye A, Rouault-Pierre K, Strullu M, et al. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia. 2019;34(7):1973–1668. doi:10.1038/s41375-019-0662-y.
   Web of Science ®Google Scholar
• Louka E, Povinelli B, Rodriguez-Meira A, et al. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia. J Exp Med. 2021;218(2):e20180853.
   PubMed Web of Science ®Google Scholar
• Krombholz CF, Gallego-Villar L, Sahoo SS, et al. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia. Leukemia. 2019;33(7):1805–1810. doi:10.1038/s41375-018-0343-2.
   PubMed Web of Science ®Google Scholar
• Wang J, Racjak J, Koleci N, et al. Inhibition of the “don’t eat me signal” CD47 to prevent relapse in juvenile myelomonocytic leukemia. Klin Padiatr. 2023;235(03):0060.
   Google Scholar
• Pasupuleti SK, Chao K, Ramdas B, et al. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia. Mol Ther. 2023;31(4):986–1001. doi:10.1016/j.ymthe.2023.01.030.
   PubMed Web of Science ®Google Scholar
• Kong G, Wunderlich M, Yang D, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest. 2014;124(6):2762–2773. doi:10.1172/JCI74182.
   PubMed Web of Science ®Google Scholar
• Chang T, Krisman K, Theobald EH, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1):335–339. doi:10.1172/JCI63193.
   PubMed Web of Science ®Google Scholar
• Lyubynska N, Gorman MF, Lauchle JO, et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011;3(76):76ra27. doi:10.1126/scitranslmed.3001069.
   PubMed Web of Science ®Google Scholar
• Niemeyer CM. JMML genomics and decisions. Hematology Am Soc Hematol Educ Program. 2018;2018(1):307–312. doi:10.1182/asheducation-2018.1.307.
   PubMedGoogle Scholar
• Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326–1333. doi:10.1038/ng.3400.
   PubMed Web of Science ®Google Scholar
• Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5(1):5694. doi:10.1038/ncomms6694.
   PubMedGoogle Scholar
• Zeiser R. Trametinib. Recent Results Cancer Res. 2014;201:241–248.
   PubMedGoogle Scholar
• Hashemzadeh S, Ramezani F, Rafii-Tabar H. Study of molecular mechanism of the interaction between MEK1/2 and trametinib with docking and molecular dynamic simulation. Interdiscip Sci. 2019;11(1):115–124. doi:10.1007/s12539-018-0305-4.
   PubMed Web of Science ®Google Scholar
• Vitiello PP, Cardone C, Martini G, et al. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Exp Clin Cancer Res. 2019;38(1):41. doi:10.1186/s13046-019-1035-0.
   PubMedGoogle Scholar
• Pomeroy EJ, Lee LA, Lee RDW, et al. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene. 2017;36(23):3263–3273. doi:10.1038/onc.2016.471.
   PubMed Web of Science ®Google Scholar
• Stieglitz E, Loh ML, Meyer J, et al. MEK inhibition demonstrates activity in relapsed, refractory patients with juvenile myelomonocytic leukemia: results from COG study ADVL1521. Blood. 2021;138(Supplement 1):3679–3679. doi:10.1182/blood-2021-144850.
   Google Scholar
• Li J, Li J, Hu T, et al. Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7. Leuk Lymphoma. 2022;63(9):2238–2242. doi:10.1080/10428194.2022.2067998.
   PubMed Web of Science ®Google Scholar
• Kerstjens M, Pinhancos SS, Castro PG, et al. Trametinib inhibits. Haematologica. 2018;103(4):e147–e150. doi:10.3324/haematol.2017.174060.
   PubMedGoogle Scholar
• Jones CL, Gearheart CM, Fosmire S, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015;126(19):2202–2212. doi:10.1182/blood-2015-04-639138.
   PubMed Web of Science ®Google Scholar
• Hofmans M, Lammens T, Depreter B, et al. Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia. Sci Rep. 2021;11(1):2801. doi:10.1038/s41598-021-82509-5.
   PubMed Web of Science ®Google Scholar
• Yan Y, Dong L, Chen C, et al. JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β. Blood Adv. 2022;6(1):200–206. doi:10.1182/bloodadvances.2021005089.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Ito M, Yamamoto T, et al. Engraftment of NOD/SCID/gammac(null) mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;130(1):51–57. doi:10.1111/j.1365-2141.2005.05578.x.
   PubMed Web of Science ®Google Scholar
• Notta F, Mullighan CG, Wang JCY, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;469(7330):362–367. doi:10.1038/nature09733.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid-leukemia after transplantation into scid mice. Nature. 1994;367(6464):645–648. doi:10.1038/367645a0.
   PubMed Web of Science ®Google Scholar
• Díaz de la Guardia R, Velasco-Hernandez T, Gutiérrez-Agüera F, et al. Engraftment characterization of risk-stratified AML in NSGS mice. Blood Adv. 2021;5(23):4842–4854. doi:10.1182/bloodadvances.2020003958.
   PubMed Web of Science ®Google Scholar
• Behnert A, Meyer J, Parsa J-Y, et al. Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia. 2022;36(1):279–282. doi:10.1038/s41375-021-01331-0.
   PubMed Web of Science ®Google Scholar
• Fujino T, Goyama S, Sugiura Y, et al. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nat Commun. 2021;12(1):1826. doi:10.1038/s41467-021-22053-y.
   PubMed Web of Science ®Google Scholar